Overview

Capivasertib China PK Study

Status:
Recruiting

Trial end date:
2022-07-29

Target enrollment:

Participant gender:

Summary

This is an open-label, 2-part Phase I study to assess the PK, safety and tolerability of capivasertib as monotherapy and in combination with paclitaxel in Chinese participants with advanced solid tumours

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

Paclitaxel